Recruiting studies: Xelox

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490 Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebreli
Phase 2 · 1 location(s) · The Fourth Affiliated Hospital of Zhejiang University School · NCT06282445 XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302 BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312 FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis
Phase 2 · 1 location(s) · Hua Jiang · NCT06801665 Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383 Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative G
Phase 3 · 10 location(s) · Sun Yat-sen University · NCT05918094 Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric
Phase 1/Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07334431 Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Phase 3 · 1 location(s) · Chinese University of Hong Kong · NCT05264896 Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06482788 XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05494060 Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Phase 3 · 1 location(s) · Hallym University Medical Center · NCT04787354 First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06070740 A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Pa
Phase 2 · 2 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT06885385 AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Phase 2 · 1 location(s) · Harbin Medical University · NCT06196697 Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2 · 1 location(s) · Peking University · NCT06023758 The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Phase 2 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT05536102 XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1/Phase 2 · 2 location(s) · West China Hospital · NCT06742411 XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction
Phase 2 · 1 location(s) · Xiaofeng Chen · NCT06091423 Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adju
Phase 2 · 1 location(s) · Nizhny Novgorod Regional Clinical Oncology Center · NCT06888843 A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal
Phase 3 · 208 location(s) · Shanghai Henlius Biotech · NCT06532006 Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
Phase 2 · 29 location(s) · Qilu Hospital of Shandong University · NCT06932068 Study of IBI363 in Patients with Advanced First-line Gastric Cancer
Phase 1 · 1 location(s) · Xiangdong Cheng · NCT06610799 Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Zhen-Hai Lu · NCT05228431 A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy
Phase 2/Phase 3 · 5 location(s) · Shanghai Henlius Biotech · NCT04547166 Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Phase 3 · 7 location(s) · Centre Leon Berard · NCT06346197 Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06383559 A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophagea
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06506292

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.